New & Notable
Blackstone closes $6.3B fund for life sciences investing
It’s the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.
— BioPharma Dive
Eli Lilly expands Insilico pact with $2.75B AI drug discovery deal
The expanded partnership gives Lilly global rights to Insilico Medicine's preclinical oral therapies, deepening its push into AI-driven R&D.
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second Phase 3 trial.
— BioPharma Dive
GLP-1 drugs show promise in managing chronic migraines
Chronic migraine patients taking GLP-1s are associated with fewer ER visits, hospitalizations and treatment interventions than those taking a common first-line migraine drug, a study shows.
Novo uses FDA voucher to win speedy approval of higher-dose Wegovy
— BioPharma DiveFederal court blocks RFK Jr.’s moves to upend US vaccine policy
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Structure's GLP-1 pill shows 'injectable-like efficacy' in a mid-stage obesity study
Structure Therapeutics' GLP-1 pill, aleniglipron, triggered up to 16.2% continued weight loss in a phase 2 obesity trial, reaffirming its "best in class" potential.
-
Lilly warns of impurities in compounded tirzepatide containing B12
Eli Lilly says compounded tirzepatide products mixed with vitamin B12 have been found to form impurities that could pose safety risks.
-
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial
Regeneron's dual GLP-1/GIP obesity shot, licensed from Hansoh Pharma, achieved phase 3 weight-loss results that come close to those of Lilly's Zepbound, but with better GI tolerability.
-
Roche, Zealand tout the tolerability of their amylin obesity drug
The Roche–Zealand amylin obesity drug, petrelintide, delivered up to 10.7% weight loss in a phase 2 obesity trial with a "placebo-like tolerability" profile, the companies say.
-
Lilly rolls out Employer Connect to close obesity coverage gaps
Eli Lilly debuts Employer Connect, a direct-to-employer platform that helps companies make its GLP-1 obesity drug, Zepbound, more affordable and accessible for employees.
-
FDA continues crackdown on DTC advertising for compounded GLP-1s
Continuing its crackdown on direct-to-consumer advertising, the FDA has sent 30 more warning letters to companies making deceptive claims about their compounded GLP-1 products.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.